Backers included fifteen new shareholders. In conjunction with the funding, Stacy Hock and Rhonda Rhyne joined the Aminex Board of Directors.
The company intends to use the funds to finalize preclinical testing and prepare for Phase 1/2A human clinical trials to start midyear 2016.
Led by Jim Skaggs, chief executive officer and chairman, Aminex Therapeutics is a drug development company focused on discovery, development, and commercialization of suppressor cell modulators (SCM), a new class of small molecule cancer immunotherapies which enable the immune system to attack cancer by regulating myeloid-derived suppressor cells.
The company has demonstrated, in animal trials, the potential of its lead drug, AMX-513, to be effective alone and to improve overall therapy when used in combination with other cancer treatments.
FinSMEs
10/11/2015